English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Select site language

Ranexa (Latixa) (ranolazine) – Conditions or restrictions regarding supply and use - C01EB18

Updated on site: 09-Oct-2017

Medication nameRanexa (Latixa)
ATC CodeC01EB18
Substanceranolazine
ManufacturerMenarini International Operations Luxembourg S.A. (MIOL)

A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Fine Foods N.T.M. SpA Via dell’Artigianato 8/10 24041 Brembate (BG)

Italy

or

Menarini - Von Heyden GmbH

Leipziger Straβe 7-13

01097 Dresden

Germany

or

Berlin-Chemie AG

Glienicker Weg 125

12489 Berlin

Germany

or

Fine Foods N.T.M. SpA

Via R. Follereau 25

24027 Nembro (BG)

Italy

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP shall be submitted every three years.

When the submission of a PSUR and the update of a RMP coincide, they should be submitted at the same time.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Additional risk minimisation measures

The PAC – which is inserted inside the carton box - must include the following key messages (see also annex IIIA):

Health Care Professional information

The PAC should include the following information for the healthcare professional information regarding Ranexa:

To refer to the Ranexa SPC prior to prescribing any medications to the patient, as there are potential drug interactions which should be taken into consideration.

Ranexa is contraindicated in patients taking:

Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone)

Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone

A dose reduction of Ranexa may be needed in combination with:

Moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole)

P-gp inhibitors (e.g. ciclosporin, verapamil)

Caution should be exercised when prescribing Ranexa to patients:

Taking certain other drugs mentioned in the product information

With certain other risk factors listed in the product information

Inform the patient about the potential for an interaction with other prescribed medicinal products and to contact his/her doctor in case of dizziness, nausea or vomiting.

Patient information

The PAC should include the following information for the patient:

That the card should be shown to any doctor involved in their treatment

That prior to Ranexa treatment the patient should tell their doctor if they have any of the following:

Kidney problems

Liver problems

Have ever had an abnormal electrocardiogram (ECG)

Is taking medications to treat epilepsy, bacterial or fungal infections, HIV infection, depression or heart rhythm disorders

Is taking the herbal remedy St John’s Wort

Is taking allergy medicines

Is taking medications to reduce cholesterol

Is taking medication to reduce the risk of transplanted organ rejection

That during treatment with Ranexa the patient should:

Not drink Grapefruit Juice

Call their doctor if they feel dizzy or sick, become sick or experience any unexpected symptoms after starting Ranexa.

To refer to the Ranexa package leaflet for more information.

To ensure to take a list of all their other medicines with them at any visit to the health care professional.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed